NCT02429193View on ClinicalTrials.gov

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2019

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

Abiraterone + prednisone

Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)

DRUG

Enzalutamide

Enzalutamide (160 mg/day p.o.)

Trial Locations (2)

V5Z 4E6

British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02429193 - Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA | Biotech Hunter | Biotech Hunter